Do analysts recommend PRFX or LIPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, PRFX or LIPO?

Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PainReform $20K 51.77 -$5.02M -$736.66 N/A Lipella Pharmaceuticals $536.36K 0.28 -$5.02M -$2.42 N/A

Do analysts prefer SLXN or LIPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer LIPO or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 3,788.89%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Lipella Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SCNI or LIPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Lipella Pharmaceuticals (LIPO) Competitors

$0.03 -0.03 (-49.38%)

As of 07/17/2026 03:54 PM Eastern

Compare

LIPO vs. PRFX, SLXN, SBFM, NMTR, and SCNI

Should you buy Lipella Pharmaceuticals stock or one of its competitors? MarketBeat compares Lipella Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipella Pharmaceuticals include PainReform (PRFX), Silexion Therapeutics (SLXN), Sunshine Biopharma (SBFM), 9 Meters Biopharma (NMTR), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "pharmaceutical products" industry.

How does Lipella Pharmaceuticals compare to PainReform?

PainReform (NASDAQ:PRFX) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	51.77	-$5.02M	-$736.66	N/A
Lipella Pharmaceuticals	$536.36K	0.28	-$5.02M	-$2.42	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

37.3% of PainReform shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PainReform has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. PainReform's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%

In the previous week, PainReform had 2 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 2 mentions for PainReform and 0 mentions for Lipella Pharmaceuticals. PainReform's average media sentiment score of 0.47 beat Lipella Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Neutral
Lipella Pharmaceuticals	Neutral

PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Summary

PainReform beats Lipella Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Silexion Therapeutics?

Silexion Therapeutics (NASDAQ:SLXN) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Silexion Therapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-516.86%	-176.68%
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%

Silexion Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for Lipella Pharmaceuticals. Silexion Therapeutics' average media sentiment score of 1.87 beat Lipella Pharmaceuticals' score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silexion Therapeutics	Very Positive
Lipella Pharmaceuticals	Neutral

11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 4.1% of Silexion Therapeutics shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lipella Pharmaceuticals has higher revenue and earnings than Silexion Therapeutics. Silexion Therapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$80.50	N/A
Lipella Pharmaceuticals	$536.36K	0.28	-$5.02M	-$2.42	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Lipella Pharmaceuticals beats Silexion Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 3,788.89%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Lipella Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lipella Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Sunshine Biopharma has a net margin of -18.45% compared to Lipella Pharmaceuticals' net margin of -988.83%. Sunshine Biopharma's return on equity of -27.75% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

In the previous week, Sunshine Biopharma's average media sentiment score of 1.45 beat Lipella Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Sunshine Biopharma	Positive

Lipella Pharmaceuticals has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.28	-$5.02M	-$2.42	N/A
Sunshine Biopharma	$36.31M	0.02	-$5.97M	-$12.90	N/A

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sunshine Biopharma beats Lipella Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to 9 Meters Biopharma?

Lipella Pharmaceuticals (NASDAQ:LIPO) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lipella Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Lipella Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.28	-$5.02M	-$2.42	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
9 Meters Biopharma	Neutral

9 Meters Biopharma has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

Lipella Pharmaceuticals beats 9 Meters Biopharma on 6 of the 9 factors compared between the two stocks.

How does Lipella Pharmaceuticals compare to Scinai Immunotherapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lipella Pharmaceuticals has lower revenue, but higher earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	0.76	-$8.31M	-$1.06	N/A
Lipella Pharmaceuticals	$536.36K	0.28	-$5.02M	-$2.42	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 1.44 beat Lipella Pharmaceuticals' score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Positive
Lipella Pharmaceuticals	Neutral

Scinai Immunotherapeutics has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Scinai Immunotherapeutics' return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, Lipella Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Lipella Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Lipella Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIPO vs. The Competition

Export

Metric	Lipella Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151K	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-0.01	20.85	27.14	23.89
Price / Sales	0.28	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	0.02	8.26	10.69	6.18
Net Income	-$5.02M	$23.83M	$3.59B	$331.73M
7 Day Performance	N/A	-3.48%	-2.18%	-2.09%
1 Month Performance	N/A	2.58%	1.63%	-2.19%
1 Year Performance	N/A	45.93%	25.56%	17.20%

Lipella Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIPO Lipella Pharmaceuticals	N/A	$0.03 -49.4%	N/A	-95.7%	$151K	$536.36K	N/A	4	Gap Down High Trading Volume
PRFX PainReform	0.4107 of 5 stars	$1.27 -5.2%	N/A	-84.0%	$1.16M	$20K	N/A	4	News Coverage Short Interest Increase
SLXN Silexion Therapeutics	1.512 of 5 stars	$2.64 -3.6%	N/A	-98.0%	$1.15M	N/A	N/A	N/A	News Coverage Positive News Gap Down
SBFM Sunshine Biopharma	3.0099 of 5 stars	$2.12 +1.9%	$70.00 +3,201.9%	-88.8%	$1.04M	$36.31M	N/A	3	Short Interest Decrease
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$1.04M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIPO) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipella Pharmaceuticals (LIPO) Competitors

LIPO vs. PRFX, SLXN, SBFM, NMTR, and SCNI

How does Lipella Pharmaceuticals compare to PainReform?

Summary

How does Lipella Pharmaceuticals compare to Silexion Therapeutics?

Summary

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Summary

How does Lipella Pharmaceuticals compare to 9 Meters Biopharma?

Summary

How does Lipella Pharmaceuticals compare to Scinai Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO vs. The Competition

Lipella Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipella Pharmaceuticals (LIPO) Competitors

LIPO vs. PRFX, SLXN, SBFM, NMTR, and SCNI

How does Lipella Pharmaceuticals compare to PainReform?

Which has preferable earnings & valuation, PRFX or LIPO?

Do analysts recommend PRFX or LIPO?

Do insiders and institutionals believe in PRFX or LIPO?

Is PRFX or LIPO more profitable?

Does the media favor PRFX or LIPO?

Which has more volatility & risk, PRFX or LIPO?

Summary

How does Lipella Pharmaceuticals compare to Silexion Therapeutics?

Is SLXN or LIPO more profitable?

Which has more volatility & risk, SLXN or LIPO?

Does the media prefer SLXN or LIPO?

Do insiders and institutionals have more ownership in SLXN or LIPO?

Which has stronger valuation & earnings, SLXN or LIPO?

Do analysts prefer SLXN or LIPO?

Summary

How does Lipella Pharmaceuticals compare to Sunshine Biopharma?

Do analysts prefer LIPO or SBFM?

Which has more risk & volatility, LIPO or SBFM?

Is LIPO or SBFM more profitable?

Does the media refer more to LIPO or SBFM?

Which has stronger earnings & valuation, LIPO or SBFM?

Do institutionals and insiders have more ownership in LIPO or SBFM?

Summary

How does Lipella Pharmaceuticals compare to 9 Meters Biopharma?

Do institutionals and insiders believe in LIPO or NMTR?

Which has more volatility and risk, LIPO or NMTR?

Which has better earnings & valuation, LIPO or NMTR?

Does the media favor LIPO or NMTR?

Is LIPO or NMTR more profitable?

Summary

How does Lipella Pharmaceuticals compare to Scinai Immunotherapeutics?

Do insiders & institutionals believe in SCNI or LIPO?

Which has better valuation and earnings, SCNI or LIPO?

Do analysts rate SCNI or LIPO?

Does the media prefer SCNI or LIPO?

Is SCNI or LIPO more profitable?

Which has more risk and volatility, SCNI or LIPO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO vs. The Competition

Lipella Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools